Full Press Release Details
CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress.
CRSP
CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress
Key Takeaway: CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension